

Today's issue of PD

Pharmacy Daily today features three pages of news, including our **Beauty & Wellness** feature, plus full pages from:

- Dermal Therapy
- Glucojel

A hint of mocha

DERMAL Therapy has introduced Mocha Brown ultra-moisturising tinted lip balm, providing long-lasting colour with a glossy, non-sticky finish - more on **page four**.

Glucojel glucofest

GLUCOJEL is giving customers the chance to win a year's supply of their favourite Glucojel products.

Entries open 20 Apr, so order your free POS today - for more details see **page five**.

TGA takes next steps on Andrographis

THE Therapeutic Goods Administration (TGA) has begun consultation on a proposal to remove *Andrographis paniculata* (Andrographis) from the list of permitted ingredients in listed medicines, following a concerning number of anaphylaxis cases (**PD** 21 Jan).

Supplements containing Andrographis are intended to provide relief from cold and flu symptoms, and are sold in pharmacies, supermarkets and health stores.

An updated safety report has been published, concluding stronger label warnings, formulation restrictions and

Vaccine definition changes

A **LEGISLATIVE** amendment to the *National Health Act 1953* has broadened the definition of 'vaccine' to include antibody-based immunising agents, such as nirsevimab (Beyfortus, Sanofi) for RSV, paving the way for inclusion on the National Immunisation Program (NIP).

Nirsevimab is an immunising monoclonal antibody therapy that contains ready-made antibodies that offer immediate protection against RSV, which is known as passive immunisation.

This differs from active immunisation provided by traditional vaccines which trigger an immune response that leads to the creation of the body's own antibodies against a virus.

While the maternal RSV vaccine (Abrysvo, Pfizer) was available to expectant mothers through the NIP in 2025, nirsevimab for infants was not, resulting in a patchwork of state and territory funding with complex and inconsistent eligibility

further education are not considered effective options to reduce the risk of anaphylaxis associated with Andrographis, suggesting it is not "low-risk" and therefore unsuitable for use as an ingredient in listed medicines.

The TGA has invited stakeholders, including health professionals, consumer organisations, medicine sponsors and industry peak bodies, to provide feedback on the product's proposed removal from the permitted ingredients list, noting it will consider all responses before making a final decision.

More info, including the safety report, can be found **HERE**.

Vita-D Mini Tablets
Supports bone health, muscle strength and calcium absorption. **NEW**

Available in **90's and 250's**
Symbion, Sigma, API & CH2

Always read the label and follow directions for use. **Petross**



criteria and guidance.

This resulted in the hospitalisation of "thousands of babies [who] slipped through the cracks and missed out on protection", explained Immunisation Foundation of Australia founder and director, Catherine Hughes.

"We hope that the first beneficiaries of this important change will be Australian babies, thousands of whom are admitted to hospital each year with severe RSV.

"Now that this legislative impediment has been removed, every effort must be made to ensure that the antibody therapy that protects against severe RSV is made available through the NIP," Hughes concluded.

It is expected that the legislative change will also enable other forms of passive immunisation to be included and supported within Australia's immunisation policies and programs. **KB**

Register now for Careers Summit

REGISTRATION for the Pharmacy Careers Summit 2026 (PCS26) has now opened, with the free, virtual event taking place on Fri 10 Jul, 2026.

The national initiative brings together pharmacists, employers and industry stakeholders to connect, explore career opportunities, and gain insights into the evolving workforce landscape.

Attendees will have the opportunity to engage directly with leading employers and organisations, hear from respected industry leaders and explore diverse career pathways across community, hospital, industry and emerging sectors.

Also available are CPD opportunities and an interactive virtual exhibition showcasing real roles and career pathways.

Sponsors include the Guild, Symbion, the Pharmaceutical Society of Australia and Pharmacists' Support Service, with **Pharmacy Daily** the event's media partner.

Learn more **HERE**.

sukin
AUSTRALIAN • NATURAL

SUKIN SIGNATURE RANGE
Your Head-to-Toe Routine, Naturally.

Available through major wholesalers. Contact your Pharmabroker Representative or call 0288789777 for more details.



For Pharmacy Participation
Register your pharmacy to display the TePe Consumer Promotion
Consumer Promotion: 1 x \$5,000 major prize + 40 x \$150 minor prizes

REGISTER & REQUEST POS



POS available while stocks last*



*POS may vary from items shown. Consumer Promotion runs 6.4. - 28.6.2026. Full consumer T&C <https://tepepromo.com.au/>

Editor's Choice: New postpartum product range is Due at Priceline

POSTPARTUM recovery range Due has signed its first major pharmacy partnership through Priceline.

Developed by the founders of Australian parenting retailer The Memo, the range is aimed at new mums and features hero products such as After (Pants) Party disposable underwear (RRP \$15.95) designed to be worn immediately after birth; Nip Magic to sooth inflamed or sensitive nipples (RRP \$84.95); and Belly Glide body oil (RRP \$59.95).

Other highlights of the range include Peri Cloud (RRP \$38.95) to calm the perineal area and Booby Soothers (RRP \$34.95), ice and heat packs that provide comfort



during breastfeeding.

"At Priceline Pharmacy, we know our customers are looking for trusted, accessible health and wellbeing support at every stage of life," said Karly Georgiou, GM of merchandise.

"The addition of Due to our mum and bub range allows us to better support mums during the postpartum period with practical, solutions-focused products, available at a time when care and convenience really matter."

New look Essano launch



AFFORDABLE New Zealand-based skincare brand Essano has undergone a brand transformation, reformulating and expanding its Hydration+ product range with a brand-new look.

Added to the range is Hyaluronic Serum (RRP \$26.95), Cica Repair Milk Toner (RRP \$21.99), The Hyaluronic Edit (RRP \$26.99) and Makeup Remover Cleansing Wipes (RRP \$8.99).

The new Hydration+ products feature four molecular weights of hyaluronic acid, combined with ceramide complex, niacinamide and cold-pressed organic rosehip oil, delivering long-lasting hydration and barrier protection.

Together, the ingredients work to support collagen and overall skin resilience and restore lipid balance for lasting comfort and glow.

Essano's refreshed, reformulated product range in its new blue and ivory palette is now available at pharmacies nationwide.

Revlon photo ready

REVLON'S new PhotoReady Lifting Brow Gel (RRP \$28) is a lightweight product that helps to sculpt, lift and set the brows, while also nourishing the hair, thanks to Provitamin B5 in the formulation.

Available in four flexible, buildable shades, including clear, soft taupe, warm medium brown, and rich dark brown.



Nioxin launches Age Defense haircare products



NIOXIN has released a new shampoo and conditioner in its Age Defense range, which is designed to rejuvenate the scalp, support hair follicles and maintain melanin production.

The products aim to create volume shine and preserve natural hair colour, thanks to its blend of ingredients including niacinamide and nutritive+ complex.

Nioxin's Age Defense Shampoo is formulated to target the early signs of hair ageing including thinning, dullness and greying, while removing buildup and impurities on the scalp.

Meanwhile, the lightweight conditioner with hyaluronic acid and caffeine provides deep moisturisation and strengthens the hair against breakage.

Want to feature on this page?

email advertising@pharmacydaily.com.au to find out more

Beauty & Wellness
by Pharmacy Daily

LEASE RENEWAL COMING UP?
Don't Panic. Actually, Panic A Bit!

Register to Lease+ for free and access resources for your lease!

Lease+ **\$0 FOREVER FREE** **TOTAL VALUE \$1,980**





Dispensary Corner

AFTER horrifying readers with insights into the ravages of air travel on skin health (*PD* 31 Mar), Fresha beauty expert Danielle Louise has turned her attention to the skin and hair devastation inflicted by cruising - including tips on which cabins to avoid.

"People often think of cruises as relaxing, but from a beauty point of view, they can be quite intense," Louise said.

"You have sea air, wind, sun exposure, pool chlorine, cabin air conditioning and often more washing than usual.

"All of that can strip moisture from the skin and leave hair feeling rough, dry or harder to manage," she explained.

The worst cabins, she said, are balcony suites, because you may be tempted to spend more time outside in the sun, wind and salt air, and rooms near the pool deck with their "easy access to chlorine".

Meanwhile, cabins with lots of noise from restaurants, night clubs, elevators and people congregating outside your door at 2am to natter after a few drinks, may present sleep challenges - leading to puffiness and tired-looking skin.

Her top tips for avoiding all this damage include wearing sunscreen, using a moisture-rich barrier after showering, packing a hair mask, rinsing chlorine from hair straight after swimming, wearing a hat, avoiding over-washing of hair, and drinking water regularly throughout the day.

And with all that, bon voyage.

Cannabis no help for mental health

THE largest-ever review of the safety and efficacy of medicinal cannabis across a range of mental health conditions has found no evidence it is effective in treating anxiety, depression or post-traumatic stress disorder (PTSD).

Conducted by researchers from the University of Sydney, the study comes as more than 700,000 Australians have reported using medicinal cannabis, with over one million prescription approvals and a tripling of sales of cannabinoid medications in Australia over the past four years.

There was some evidence - albeit low quality - to suggest that medicinal cannabis could potentially be beneficial for some conditions, such as the treatment of cannabis use disorder (cannabis dependency), autism, insomnia, and tics or Tourette's syndrome.

But the authors said that in the absence of robust medical or counselling support, the use of medicinal cannabis in these cases is rarely justified.

The study's lead author, Dr Jack Wilson at the Matilda Centre, said the results call into question the approval of medicinal cannabis for the treatment of depression, anxiety and PTSD.

"Though our paper didn't



specifically look at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments," he said.

Responding to concerns from peak bodies including the Pharmacy Guild of Australia and the Australian Medical Association around the prescribing and dispensing of medicinal cannabis, the Therapeutic Goods Administration (TGA) initiated a review of the regulatory oversight of medicinal cannabis (*PD* 24 Feb).

Dr Wilson suggested the study "may support the TGA and clinicians to make evidence-based decisions, helping to ensure patients receive effective treatments while minimising harm from ineffective or unsafe cannabis products" - read the paper [HERE](#). *KB*

FDA approves orforglipron

THE US Food and Drug Administration (FDA) has approved oral weight loss drug orforglipron (Foundayo, Eli Lilly) for adults with obesity, or overweight with weight-related medical problems.

"People living with obesity need treatment options that meet them where they are - and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," said Dr Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston.

"With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials - addressing both the clinical realities of obesity and the practical challenges patients face every day," she added.

In addition to being tested for weight loss, studies have also found orforglipron delivered significant improvements in glycaemic control in patients with type 2 diabetes (*PD* 21 Oct 2025).

Sales of the drug commenced this week, and starting at around US\$149 (A\$210) per month for self-pay patients, the drug is significantly cheaper than Ozempic, which costs from US\$350 (A\$495).

Lilly has submitted the drug for weight management and/or T2D in over 40 countries - including Australia - with the FDA's approval expected to speed up the process.

TGA sunscreen review and webinar

THE Therapeutic Goods Administration (TGA) has opened a public consultation looking into improvements to the regulation of sunscreens in Australia, and is inviting stakeholders to provide a response by 23 May 2026.

Up for consideration are improved reliability of SPF testing, faster adoption of new test methods, stronger oversight

of test labs, enhanced quality assurance and greater consistency in claims - click [HERE](#) for details.

The regulator will also host a webinar on 14 Apr 2026 at 1pm AEST to provide stakeholders with an overview of the key proposals in the consultation paper, with an opportunity to ask questions of the TGA's expert panel - register [HERE](#).

Australia's No.1 Lip Balm* Now With a Hint of Tint!



New



- ✓ Clinically tested*
- ✓ Long-lasting colour
- ✓ Glossy, not sticky

Find out more about
Dermal Therapy's Latest
Innovations

[CLICK HERE](#)

*Data on file

www.dermaltherapy.com.au

GLUCO FEST!

TASTE THE JOY

WIN THE SWEET LIFE!



TASTE THE JOY, WIN THE SWEET LIFE!

Your customers will have the chance to win a year's supply of their favourite Glucojel products.*

Help us celebrate Glucofest by ordering your campaign POS. And don't forget our Everyday Buying Deal to stock up on Glucojel!

Entries open 20 April 2026.

OUR PROFIT IS YOUR PROFIT.

Visit goldx.com.au/glucojel for more info

*T&C's apply

